<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The deletion of the long arm of chromosome 20, or del(20q), is a common cytogenetic abnormality in various myeloid disorders but is less commonly seen in lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Here we report a case of <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">Waldenstr√∂m macroglobulinemia</z:e> with del(20q) as the sole cytogenetic anomaly </plain></SENT>
<SENT sid="2" pm="."><plain>No translocation including immunoglobulin genes was identified by spectral karyotyping (SKY) analysis </plain></SENT>
<SENT sid="3" pm="."><plain>Reviewing <z:hpo ids='HP_0000001'>all</z:hpo> 11 reported cases of <z:e sem="disease" ids="C1136084" disease_type="Neoplastic Process" abbrv="">plasma cell dyscrasia</z:e> possessing sole del(20q), including our case, none of 4 cases with del(20q) as an initial anomaly developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>-<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), but at least 3 cases with del(20q) appearing after chemotherapy developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> at or after the time of del(20q) </plain></SENT>
<SENT sid="4" pm="."><plain>We propose that the del(20q) may have different clinical significance in <z:e sem="disease" ids="C1136084" disease_type="Neoplastic Process" abbrv="">plasma cell dyscrasia</z:e>: one is when del(20q) appears at diagnosis and may involve the initial event of <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e>, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> risk </plain></SENT>
</text></document>